A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM-C2
- Sponsors United Therapeutics Corporation
- 29 Aug 2022 Results of post-hoc analysis (FREEDOM-C and FREEDOM-C2) assessing efficacy and dose-response relationship of oral treprostinil in pulmonary arterial hypertension patients on monotherapy or dual background therapy, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
- 24 May 2017 Results of secondary analysis (n=178) from this trial assessing correlation between increased endothelial activation with mitochondrial dysfunction in patients with pulmonary arterial hypertension, presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results of secondary analysis from FREEDOM-C2 trial presented at the 113th International Conference of the American Thoracic Society